A CASCADE Of Trouble For Seattle Genetics' AML Drug SGN-CD33A

Seattle Genetics will discontinue all trials of vadastuximab talrine, including the Phase III CASCADE trial in frontline older acute myeloid leukemia patients after a higher rate of deaths was seen.

 Leukemia cell (blast cell)

A big setback for Seattle Genetics Inc.'s vadastuximab talirine (SGN-CD33A) in a Phase III acute myeloid leukemia trial will put more pressure on the company's expansion strategy for the currently-marketed lymphoma drug Adcetris (brentuximab vedotin) to drive growth in the near-term.

The Bothell, Washington-based biotech announced June 19 that it is discontinuing all clinical trials studying vadastuximab talirine, including the Phase...

More from Clinical Trials

More from R&D